ProMIS Neurosciences (NASDAQ:PMN), a biotechnology company developing antibody therapeutics for neurodegenerative diseases, reported its full-year 2025 financial results and provided a comprehensive corporate update on March 25, 2026.
The company’s performance over the past year was marked by the rapid clinical advancement of its lead candidate and a transformational shift in its capital structure.
A primary highlight for the fiscal year was the completion of patient enrollment for the PRECISE-AD Phase 1b clinical trial.
The study, which evaluates PMN310 in patients with early Alzheimer’s disease, was oversubscribed, reaching a final total of 144 participants across three dosing cohorts.
PMN310 is specifically engineered to target toxic soluble amyloid-beta oligomers while avoiding amyloid plaque—a design intended to reduce the risk of Amyloid-Related Imaging Abnormalities (ARIA).
To date, the company reports that PMN310 has demonstrated a favorable safety profile with no treatment-related serious adverse events or cases of ARIA.
Financially, ProMIS significantly strengthened its balance sheet in early 2026.
Following a net loss of $39.7 million for 2025, the company closed a private placement financing in February 2026, securing $75.5 million in up-front gross proceeds.
This funding, which could reach up to $175 million upon the exercise of warrants, is expected to support operations and clinical development into late 2027.
Looking ahead, the company has established a clear sequence of catalysts for the PRECISE-AD program.
Six-month blinded assessments are scheduled for completion in the second quarter of 2026, with a blinded interim analysis expected in early Q3 2026.
These milestones will lead toward the anticipated release of 12-month top-line data in early 2027.
Beyond Alzheimer’s, ProMIS continues to advance its preclinical pipeline, including PMN267 for ALS and PMN442 for Parkinson’s disease, both of which are currently in IND-enabling preparations.